Skip to main content

Table 1 Selected publications between 2005 and 2019 in Web of Science database according to the following search terms: (mesenchymal stem cells) AND (fetal bovine serum OR fetal bovine calf) AND (human platelet lysate), its acronyms and complete bibliography checking

From: Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review

Author Type of cell % Additive hPL manufacturing Type of lysis/Inactivation Filter Diff. Line T. Feeding MO P.I. CD
(Kong et al. 2019) hUMC-MSCs 10% FBS, 10% hPL, 10% HS I N.M. N.M 1 3–4 days 2 2 1
(Barro et al. 2019) BM-MSCs FBS, hPL, i-hPL Aph SD + UV, FT 0.22/0.1 µm 3 3–4 days 1 1 1
(Lensch et al. 2018) ASC-MSCs FBS 10%, xeno free media I N.M. N.M 1 3–4 days 1 1 1
(Haack-Sørensen et al. 2018) ASC-MSCs 10% FBS, 5% hPL I N.M. N.M 1 N.M. 3 1 1
(Dessels et al. 2019) ASC-MSCs FBS 10%, 10%, 5% hPL BC FT 0.22 µm 0 3–4 days 1 1 1
(Becherucci et al. 2018) BM-MSCs FBS 10%, hPL 5% BC FT 0.45/0.22 µm 1 3–4 days 1 1 1
(Chen et al. 2019) hUMC-MSCs 10% FBS, 6.55%(FTPL), 6.50%(GBPL), 7.50% (SDPL), 6.72% GBHPL Aph SD + Ca, FT 0.22 µm A−/B+ 3–4 days 1 1 1
(Ren et al. 2018) BM-MSCs 20% FBS, 10% HPGF-C18 Aph SD 0.2 µm 0 3–4 days 2 2 1
(Kandoi et al. 2018) hUMC-MSCs 20% FBS, 10%, 5% hPL N.M. FT N.M 1 3–4 days 2 1 1
(Phetfong et al. 2017) ASC-MSCs 10% FBS, 10% hPL, 10% hPL + hPlasma N.M. FT 0.2 µm B 1 day 1 1 1
(Søndergaard et al. 2017) ASC-MSCs 10% FBS, 5% hPL I N.M. N.M 0 3–4 days 1 1 1
(Mangum et al. 2017) ASC-MSCs FBS 10%, hPL 10% I N.M. N.M A−/B+ N.M. 3 1 2
(Bernardi et al. 2017) BM-MSCs 10% FBS, 10%, 7.5%, 5% hPL, 10% 7.5% 5% PR-SRGF Aph Ca, FT 70 µm 1 3–4 days 3 2 1
(Pierce et al. 2017) BM-MSCs 10% FBS, 10% PL-S, 10% PL-P PRP Ca N.M 0 3–4 days 3 1 2
(Fernandez-Rebollo et al. 2017) BM-MSCs 10%FBS, 10% hPL Aph FT 0.2 µm 1 N.M. 1 1 1
(Matthyssen et al. 2017) hC-MSCs FBS, hPL, hS 2.5%, 5%, 10% I N.M. N.M 1 N.M. 1 1 1
(Viau et al. 2017) BM-MSCs 2-15% FBS + bFGF, hPL, PR-hPL BC UV, FT N.M 1 3–4 days 3 1 1
(Riis et al. 2016) ASC-MSCs 10% FBS, 10%, 5% hPL I N.M. N.M 0 3–4 days 4 1 2
(Escobar and Chaparro, 2016) ASC-MSCs FBS 10%, hPL 5% BC FT 0.22 µm A−/B+ 3–4 days 2 1 1
(Heathman et al. 2016) BM-MSCs 10% FBS, 10% PL I N.M. N.M 1 3–4 days 3 1 1
(Mohammadi et al. 2016) hUMC-MSCs 10% FBS, 2%, 5%, 7%, 10% PL PRP N.M. N.M 1 3–4 days 1 1 2
(Shirzad et al. 2017) hUMC-MSCs 10% FBS, 10%, 5% UCB-PL, PB-PL PRP FT N.M 3 3–4 days 2 1 2
(Suri et al. 2016) hC-MSCs 10% FBS, 10% PHPL, 10% hPL Aph FT N.M 0 N.M. 2 2 1
(Juhl et al. 2016) ASC-MSCs and BMSCs 10% FBS, 5% PLTMax, 5% hPLS, 5% hPLSP I N.M. N.M 1 3–4 days 1 1 1
(Muraglia et al. 2015) BMSCs, ASCs, UC-MSCs, T-lymph 10% FCS, 5% PPP, hPL PRP FT N.M 1 3–4 days 3 1 1
(Wagner et al. 2015) ASC-MSCs and hF 10% FBS, 5% hPL Aph FT 0.2 µm 1 N.M. 3 1 3
(Riordan et al. 2015) hUMC-MSCs 10% FBS, 5%, 7.5%, 10% XcytePLUS-hPL N.M. N.M. N.M 1 N.M. 2 1 1
(Castiglia et al. 2014) BM-MSCs 10% FBS, 10% hPL, 10% iHPL BC UV 0.2 µm 1 3–4 days 1 2 1
Trojahn Kølle et al. 2013) ASC-MSCs 10% FBS, 10% hPL PRP FT 0.2 µm 1 3–4 days 1 1 1
(Witzeneder et al. 2013) ASC-MSCs and hF 10% FBS, 5% hPLp, 5% hPLn, 10% huS BC FT N.M 1 3–4 days 2 1 3
(Kinzebach and Bieback, 2013) ASC-MSCs and BMSC 10%, 7.5%, 5%, 2.5% FBS, pHPL, tPRP BC Thr, FT 0.45 µm A−/B+ N.M. 3 1 3
(Mojica-Henshaw et al. 2013) MSCs 10%FBS, 10% hPLp, 10% hPLs PRP Ca, FT 0.22 µm A 3–4 days 3 1 1
(Bernardi et al. 2013) BM-MSCs 10% FBS, 10% PLT-FT-Ly, 7.5%, 5%, 2.5% PLT PRP Son, FT 70 µm 1 3–4 days 3 1 1
(Shanskii et al. 2013) ASC-MSCs 10/0, 7.5/2.5, 5/5, 2.5/7.5, 0/10% FBS, hPL N.M. FT N.M 0 N.M. 3 1 3
(Griffiths et al. 2013) BM-MSCs 16% FBS, 2%, 5%, 10% hPL PRP FT N.M 1 N.M. 1 1 1
(Ben Azouna et al. 2012) BM-MSCs 10%FBS, 10% FBS + 5% hPL, 10% hPL, 5% hPL Aph FT N.M AB− 3–4 days 1 1 1
(Gottipamula et al. 2012) BM-MSCs 10% FBS, 10% hPL N.M. FT N.M 3 N.M. 1 1 1
(Fekete et al. 2012) BM-MSCs 20% FBS, 10% hPL BC UV, FT 0.45/0.22 µm 1 3–4 days 3 2 1
(Schallmoser and Strunk, 2013) hUMC-MSCs 10% FBS, 2.5, 5, 10% pHPL BC, Aph FT 0.22 µm 0 N.M. 3 1 3
(Naaijkens et al. 2012) ASC-MSCs 10% FBS, 5% hPL BC FT N.M 0 3–4 days 1 1 1
(Shih et al. 2011) ASC-MSCs 10% FBS, 10% hPL N.M. SD 0.2 µm C 3–4 days 2 1 1
(Crespo-Diaz et al. 2011) ASC-MSCs and BMSCs FBS 10%, hPL 5% N.M. FT 70 µm 1 N.M. 3 1 1
(Govindasamy et al. 2011) DPSCs 10% FBS, 10% hPL PRP FT 0.40 µm 1 3–4 days 1 1 1
(Shichinohe et al. 2011) BM-MSCs 10% FBS, 5% hPL PRP FT N.M N 3–4 days 2 3 1
(Xia et al. 2011) BM-MSCs 10% FBS, 7.5% hPL Aph FT 0.22 µm A−/B+ N.M. 1 2 1
(Cholewa et al. 2011) ASC-MSCs 10% FBS, 10% hPL N.M. FT N.M 1 3–4 days 1 1 1
(Abdelrazik et al. 2011) BM-MSCs 10% FBS, 10% hPL Aph FT N.M 0 3–4 days 3 1 1
(Horn et al. 2010) BM-MSCs 10%FBS, 10% hPL BC, Aph FT 0.2 µm 1 3–4 days 2 2 1
(Blande et al. 2009) ASC-MSCs 10% FBS, 2.5%, 10% hPL N.M. FT 0.22 µm 1 1 day 1 1 2
(Bieback et al. 2009) BM-MSCs 10% FBS, 10% HS, 10% tPRP, 10% pHPL PRP Thr, FT 0.2 µm 1 3–4 days 1 1 1
(Prins et al. 2009) BM-MSCs 10% FBS, 5% hPL N.M. FT N.M 1 3–4 days 1 1 1
(Zaky et al. 2008) BM-MSCs 10% FBS, 5% hPL PRP FT N.M 1 3–4 days 1 1 3
(Schallmoser et al. 2007) BM-MSCs 10% FBS, hPL 10% PRP FT 0.22 µm 1 3–4 days 1 1 1
(Capelli et al. 2007) BM-MSCs 10% FBS, 5% hPL PRP FT N.M 1 3–4 days 2 1 1
(Reinisch et al. 2007) hUMC-MSCs 10% FBS, 10% hPL PRP FT 0.22 µm 1 3–4 days 2 1 1
(Doucet et al. 2005) BM-MSCs 10% FBS, 5% hPL Aph FT N.M A 3–4 days 3 1 1
  1. Proliferation rate (P.I.): Higher in hPL (1); No difference (2); Not mentioned (3)
  2. Immunophenotype (CD): Expression CD >/= (1); No expression or < (2); Not mentioned (3)
  3. Morphology (MO): Smaller elongated spindle shape (1); No difference (2); Not mentioned (3); Different shape (4)
  4. Differentiation lineage (Diff. Line): Not mentioned (0); No difference (1); High trilineage (3); High adipogenic (A); High osteogenic (B); High chondrogenic (C); Low adipogenic and osteogenic (AB−); Low adipogenic and high osteogenic (A−/B+); Neural differentiation (N)
  5. hPL manufacturing: Industrial (I); Buffy coat (BC); Platelet-rich plasma (PRP); Apheresis (Aph); Apheresis and/or Buffy Coat; Not mentioned (N.M.)
  6. Type of platelet lysis: Freeze/thaw (FT); Solvent/detergent inactivation (SD); Sonification (Son); Calcium addition (Ca); Thrombin activation (Thr) and/or FT; Irradiation (UV); Solvent/detergent inactivation + irradiation and/or FT (SD + UV, FT); Solvent/detergent inactivation + Ca addition and/or FT (SD + Ca, FT); Calcium addition and/or FT (Ca, FT); Irradiation and/or FT (UV, FT); Not mentioned (N.M.)
  7. Type of cells: Human umbilical cord-MSCs (hUMC-MSCs); Bone marrow-MSCs (BM-MSCs); Adipose derived-MSCs (ACS-MSCs); Human corneal stromal MSCs (hC-MSCs); Adipose derived-MSCs (ACS-MSCs) and/or human skin fibroblast (hF); Dental Pulp-MSCs (DPSCs); Adipose derived-MSCs (ACS-MSCs) and/or Bone marrow-MSCs (BM-MSCs); Not specify the source (MSCs); BM-MSCs, AT-MSCs, hUMC-MSCs, histiocytic lymphoma U-937, human chondrocyte, T-lymphocyte CD4/CD8 (Others)